Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hangzhou Meisai Biomedical Technology

Request full access

ReTime Medicine Pioneer

ChinaFounded 2019Biotech & Life Sciences

About Hangzhou Meisai Biomedical Technology

Hangzhou Meisai Biomedical Technology, operating under the name Medimscience, is a biopharmaceutical company established in 2019. The company was founded by Yuan Hong, who currently serves as the CEO, leading a team described by investors as having a deep research foundation and unique understanding of macrophage biology.

The firm concentrates its efforts on the discovery and development of innovative drugs that target macrophages, a type of white blood cell. This focus aims to address significant unmet needs in modern medicine, particularly in oncology and autoimmune diseases. Meisai is developing what it terms "First-In-Class" antibody drugs to treat conditions that have shown resistance to existing treatments. These include autoimmune disorders like Inflammatory Bowel Disease (IBD) and solid cancers, often referred to as "cold tumors" due to their low T-cell infiltration, such as colon cancer, liver cancer, and gliomas.

The company's core strategy revolves around reprogramming the tumor immune microenvironment. For cold tumors, the goal is to develop therapies that can overcome the immunosuppressive nature of these cancers, which are often resistant to PD-1/PD-L1 inhibitor treatments. In the realm of autoimmune diseases, Meisai's research focuses on modulating macrophages to eliminate abnormally activated T cells and inhibit inflammatory responses. Beyond single-target antibodies, the company is also exploring dual-target antibodies and combination strategies with chemotherapy and antibody-drug conjugates to create synergistic effects.

Since its inception, Meisai has successfully secured multiple rounds of funding. The initial angel round in July 2021 was followed by a Seed round in September 2022, led by Qiming Venture Partners, with participation from other institutional investors like Co-win Ventures and REDHILL CAPITAL. These funds are being utilized for research and development, product registration, and advancing their product pipeline toward clinical filing.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
19.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Apr 2026 $21M $83M Hongfeng Investment · Bayland Capital · Ruihua Holdings · SHC Shanghai Biomedical Fund ↗
SERIES A✓Equity / VC Sep 2022 $2.8M $11M Kaifeng Venture Capital · Ming Bioventures ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Hangzhou Meisai Biomedical Technology website traffic

Latest recorded traffic for Hangzhou Meisai Biomedical Technology is 80 monthly website visits, down 27.3% over the last three months.

Latest monthly visits80 3-month web change-27.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Hangzhou Meisai Biomedical Technology in its local ecosystem

Live from Dealroom

The Hangzhou Meisai Biomedical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Kaifeng Venture Capital
  • Ming Bioventures
  • Bayland Capital
  • Hongfeng Investment
  • Ruihua Holdings
  • SHC Shanghai Biomedical Fund
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hangzhou Meisai Biomedical Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hangzhou Meisai Biomedical Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.